Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy.
The authors describe the case of a simultaneous mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy in a 40-year-old woman. Four years before, she underwent a mitral valve replacement after the diagnosis of mitral regurgitation during benfluorex treatment (150 mg/day). This drug was reintroduced postoperatively. She presented with exercise and sometimes resting dyspnoea. The bioprosthesis and aortic valves exhibited similar histopathological lesions. Thickening and plaque deposits made by smooth muscle alpha actin- and vimentin-positive cells in a glycosaminoglycan matrix were observed. The study discusses the putative contribution of circulating progenitor cells activated by 5-HT(2B) receptor agonists in the development of drug-induced heart disease.
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université de Strasbourg, 11 rue Humann, 67085 Strasbourg, France.
Estelle
E
Ayme-Dietrich
Roland
R
Lawson
Bernard
B
Gasser
Robert
R
Dallemand
Nicolas
N
Bischoff
Laurent
L
Monassier
D000328:Adult; D001021:Aortic Valve / Q000187:drug effects / Q000473:pathology; D001705:Bioprosthesis; D017439:Cicatrix, Hypertrophic / Q000139:chemically induced; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005355:Fibrosis; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000473:pathology; D019918:Heart Valve Prosthesis Implantation / Q000379:methods; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000601:surgery
D000960:Hypolipidemic Agents; D005277:Fenfluramine; C001584:benfluorex